Ipsen (OTCMKTS:IPSEY) Shares Cross Above Two Hundred Day Moving Average – Should You Sell?

Ipsen S.A. (OTCMKTS:IPSEY)’s share price passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $29.89 and traded as high as $30.04. Ipsen shares last traded at $28.35, with a volume of 23,576 shares changing hands.

Ipsen Stock Down 7.0 %

The company’s 50 day moving average is $29.77 and its 200 day moving average is $29.89.

Ipsen Company Profile

Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.